Generic molecule: pertuzumab
Approval date: June 8
The scoop: This new targeted breast cancer drug from Genentech is designed for use in tandem with the older Herceptin. Like Herceptin, it has blockbuster potential. Forecasts put Perjeta sales at $600 million to $1 billion initially and reaching as high as $8.5 billion if it gets approved for a couple of other indications. That compares with the more than $6 billion in sales Herceptin should pump out this year for Genentech parent Roche ($RHHBY).